Bloom Burton

Newtopia Inc. is a health technology company based in Toronto, Canada, that specializes in habit change and disease prevention. Founded in 2008, Newtopia operates a proprietary virtual platform that focuses on metabolic risk reduction by creating personalized lifestyle plans informed by social, psychological, and genetic insights. The company seeks to address significant health challenges, such as obesity and chronic diseases, which are linked to unhealthy lifestyle choices and have substantial economic impacts. By utilizing genetic testing and engagement science, Newtopia aims to inspire individuals to adopt healthier behaviors. The company has demonstrated an 80% success rate with beta clients and operates on a cost-effective model, making it an attractive partner for insurers and employers looking to improve health outcomes and achieve a meaningful return on investment. Through strategic partnerships, Newtopia is positioned to scale its innovative solutions in the health engagement market.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on acquiring, developing, and commercializing innovative medicines to address unmet needs in infectious diseases. Founded in 2015, the company has a diverse anti-infective portfolio that includes several clinical candidates. These include Favipiravir for pandemic influenza and COVID-19, ATI-2307, an antifungal agent for cryptococcal meningitis and invasive candidiasis, and ATI-1501, a taste-masked oral formulation of the antibiotic metronidazole. Additionally, Appili is developing ATI-1503, which targets gram-negative bacteria, and ATI-1701, a live-attenuated vaccine for Francisella tularensis. Through its work, Appili Therapeutics aims to provide effective solutions for patients suffering from serious infections.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on acquiring, developing, and commercializing innovative medicines to address unmet needs in infectious diseases. Founded in 2015, the company has a diverse anti-infective portfolio that includes several clinical candidates. These include Favipiravir for pandemic influenza and COVID-19, ATI-2307, an antifungal agent for cryptococcal meningitis and invasive candidiasis, and ATI-1501, a taste-masked oral formulation of the antibiotic metronidazole. Additionally, Appili is developing ATI-1503, which targets gram-negative bacteria, and ATI-1701, a live-attenuated vaccine for Francisella tularensis. Through its work, Appili Therapeutics aims to provide effective solutions for patients suffering from serious infections.

AceAge is a healthcare technology company focused on creating innovative solutions to enhance health outcomes and ease the aging process. The company's flagship product, a home health appliance named Karie, serves as a personal health companion that organizes, schedules, and dispenses medications with a simple one-button interface. Designed to improve patient compliance with medication regimens, Karie aims to reduce the negative impacts associated with missed doses. By automating daily medication routines, the device minimizes human error and promotes greater patient autonomy. Karie utilizes standard multi-dose pouch packaging that can be pre-configured by pharmacists, ensuring that doses are effectively scheduled, delivered, and monitored. Through its technology, AceAge seeks to improve healthcare delivery and reduce the substantial costs associated with medication nonadherence, ultimately supporting better health outcomes for patients.

Triumvira Immunologics USA, Inc. is an immunotherapy company founded in 2015 and headquartered in Austin, Texas, with research facilities in Hamilton, Canada. The company focuses on developing innovative T cell therapies aimed at improving cancer treatment outcomes. Its primary offerings include chimeric antigen receptor (CAR) therapies and engineered T cell receptor (TCR) therapies. A key aspect of Triumvira's approach is its proprietary T cell Antigen Coupler (TAC) technology, which recruits the entire natural T cell receptor and operates independently of the major histocompatibility complex (MHC). This technology enables the development of more effective therapies for a wider array of patients suffering from both solid and liquid malignancies, as well as other diseases beyond cancer.

Antibe Therapeutics Inc. is a pharmaceutical development company focused on creating novel therapeutics to address pain, inflammation, and regenerative medicine. The company is dedicated to developing safer alternatives to traditional non-steroidal anti-inflammatory drugs (NSAIDs), which often lead to gastrointestinal complications. Its lead compound, ATB-346, is designed to treat conditions such as rheumatoid arthritis and ankylosing spondylitis, having successfully completed a Phase 2B gastrointestinal safety study. Antibe's pipeline also includes ATB-352, in preclinical development for treating gout and post-surgical pain, and ATB-340, targeting stroke and cancer. Additionally, Antibe provides various medical products, including bone graft substitutes and barrier membranes, for dental and orthopedic applications. Headquartered in Toronto, Canada, Antibe Therapeutics leverages its proprietary hydrogen sulfide platform to enhance the therapeutic potential of existing drugs while guided by a team of accomplished researchers and advisors.

Appili Therapeutics Inc. is a biopharmaceutical company based in Halifax, Canada, focused on acquiring, developing, and commercializing innovative medicines to address unmet needs in infectious diseases. Founded in 2015, the company has a diverse anti-infective portfolio that includes several clinical candidates. These include Favipiravir for pandemic influenza and COVID-19, ATI-2307, an antifungal agent for cryptococcal meningitis and invasive candidiasis, and ATI-1501, a taste-masked oral formulation of the antibiotic metronidazole. Additionally, Appili is developing ATI-1503, which targets gram-negative bacteria, and ATI-1701, a live-attenuated vaccine for Francisella tularensis. Through its work, Appili Therapeutics aims to provide effective solutions for patients suffering from serious infections.

HLS Therapeutics Inc is a specialty pharmaceutical company that focuses on the acquisition and commercialization of branded pharmaceutical products primarily in North America. The company is committed to managing the life cycles of these products after their exclusivity, ensuring that essential treatments remain accessible to patients and caregivers. HLS Therapeutics offers a range of products, including Clozaril and Vascepa, and generates revenue mainly through product sales, supplemented by royalties. Operating in Canada, the United States, and other international markets, HLS Therapeutics plays a crucial role in maintaining the availability of trusted medications.

Hamilton Thorne is a global provider of advanced laser systems and instruments for in-vitro cell applications, primarily serving the regenerative medicine research and fertility clinic markets. The company's flagship products, ZILOS-tk and XYClone laser systems, are robotic micro-surgeons that attach to standard microscopes, enhancing efficiency and precision in stem cell, embryo, and living cell procedures. Hamilton Thorne's Computer-Assisted Semen Analysis (CASA) systems are designed to improve the study of reproductive cells in various fields, including animal and human infertility, and reproductive toxicology. The company's products are used by leading research institutions, pharmaceutical companies, and fertility clinics worldwide, enabling breakthroughs in cell manipulation and research.

Bellus Health is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for rare diseases, with a particular focus on conditions affecting the kidneys. Its lead drug candidate, KIACTA™, is designed for the treatment of AA amyloidosis, a rare condition that can result in severe renal dysfunction. Following the successful completion of a Phase 3 study, the company is collaborating with Auven Therapeutics to advance KIACTA™, which is also being explored for treating sarcoidosis, an inflammatory disease affecting the lungs. Additionally, Bellus Health is developing Shigamab™, an antibody treatment for Hemolytic Uremic Syndrome, a serious condition linked to Shiga toxin-producing E. coli, which poses significant health risks, especially for children. The company's research pipeline also includes efforts to address AL amyloidosis, another rare disease characterized by the accumulation of amyloid proteins in the body. Bellus Health aims to meet the high unmet medical needs of patients suffering from these conditions through its focused therapeutic developments.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that specializes in habit change and disease prevention. Founded in 2008, Newtopia operates a proprietary virtual platform that focuses on metabolic risk reduction by creating personalized lifestyle plans informed by social, psychological, and genetic insights. The company seeks to address significant health challenges, such as obesity and chronic diseases, which are linked to unhealthy lifestyle choices and have substantial economic impacts. By utilizing genetic testing and engagement science, Newtopia aims to inspire individuals to adopt healthier behaviors. The company has demonstrated an 80% success rate with beta clients and operates on a cost-effective model, making it an attractive partner for insurers and employers looking to improve health outcomes and achieve a meaningful return on investment. Through strategic partnerships, Newtopia is positioned to scale its innovative solutions in the health engagement market.

Noden Pharma is a global specialty pharmaceutical company dedicated to acquiring and marketing prescription medicines across various therapeutic areas. The company holds exclusive worldwide rights to manufacture, market, and sell Tekturna and Tekturna HCT, which contain aliskiren, a direct renin inhibitor used in the treatment of hypertension. By focusing on international markets, Noden Pharma aims to enhance the quality of life for patients through its specialized medical solutions.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Hamilton Thorne is a global provider of advanced laser systems and instruments for in-vitro cell applications, primarily serving the regenerative medicine research and fertility clinic markets. The company's flagship products, ZILOS-tk and XYClone laser systems, are robotic micro-surgeons that attach to standard microscopes, enhancing efficiency and precision in stem cell, embryo, and living cell procedures. Hamilton Thorne's Computer-Assisted Semen Analysis (CASA) systems are designed to improve the study of reproductive cells in various fields, including animal and human infertility, and reproductive toxicology. The company's products are used by leading research institutions, pharmaceutical companies, and fertility clinics worldwide, enabling breakthroughs in cell manipulation and research.

Profound Medical Corp. is a medical technology company based in Mississauga, Canada, specializing in the development of innovative, incision-free therapeutic systems for the image-guided ablation of diseased tissue. The company’s flagship product, the TULSA-PRO system, integrates real-time magnetic resonance imaging with robotically driven thermal ultrasound to precisely ablate prostate tissue. Additionally, Profound Medical offers the Sonalleve platform, which is designed for treating uterine fibroids and managing palliative pain associated with bone metastases. By leveraging existing MRI infrastructure, the company aims to provide customizable and non-invasive treatment options that address the unmet needs of patients and clinicians. Profound Medical is committed to enhancing the standard of care through its advanced technologies and has established a co-development agreement with GE Healthcare to broaden access to its TULSA-PRO system.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Newtopia Inc. is a health technology company based in Toronto, Canada, that specializes in habit change and disease prevention. Founded in 2008, Newtopia operates a proprietary virtual platform that focuses on metabolic risk reduction by creating personalized lifestyle plans informed by social, psychological, and genetic insights. The company seeks to address significant health challenges, such as obesity and chronic diseases, which are linked to unhealthy lifestyle choices and have substantial economic impacts. By utilizing genetic testing and engagement science, Newtopia aims to inspire individuals to adopt healthier behaviors. The company has demonstrated an 80% success rate with beta clients and operates on a cost-effective model, making it an attractive partner for insurers and employers looking to improve health outcomes and achieve a meaningful return on investment. Through strategic partnerships, Newtopia is positioned to scale its innovative solutions in the health engagement market.

Knight Therapeutics Inc. is a specialty pharmaceutical company based in Montreal, Canada, engaged in the development, acquisition, in-licensing, out-licensing, marketing, and distribution of innovative prescription pharmaceuticals, consumer health products, and medical devices. The company offers a range of commercialized products, including Movantik for opioid-induced constipation, Mytesi for noninfectious diarrhea in adults with HIV or AIDS, NERLYNX for HER2-positive breast cancer, and Trelstar for prostate cancer. Additionally, Knight Therapeutics is involved in the development of treatments for conditions such as opioid addiction, chronic pain, diabetes-related eye diseases, and neurological disorders. Their product pipeline includes various therapies targeting acute migraine, HPV-associated cancers, and osteoarthritis-related pain, among others. Founded in 2013, Knight Therapeutics continues to expand its portfolio and invest in innovative life sciences solutions both in Canada and internationally.

Medicago Inc. is a biotechnology company headquartered in Quebec City, Canada, specializing in the research, development, and commercialization of vaccines. The company employs proprietary plant-based manufacturing and virus-like particle (VLP) technologies to create innovative vaccines and therapeutics for infectious diseases. Its notable product candidates include a VLP vaccine for the H5N1 pandemic influenza, which has successfully completed Phase I clinical trials, as well as an H1N1 VLP vaccine aimed at the Influenza A/California/04/09 virus and various seasonal influenza vaccines. Medicago has established collaboration agreements with organizations such as Viridis S.A. and Genopole biopark for the production of pandemic and seasonal influenza vaccines, alongside a partnership with Philip Morris International for developing a therapeutic protein with a human-compatible glycosylation pattern. Founded in 1997, Medicago is dedicated to addressing emerging public health challenges through its advanced vaccine technologies.

Oncolytics Biotech Inc. is a clinical-stage biopharmaceutical company based in Calgary, Canada, dedicated to the discovery and development of innovative cancer therapies. The company's lead product, pelareorep, is an immuno-oncology agent derived from reovirus, designed to treat solid tumors and hematological malignancies by enhancing the immune system's ability to combat cancer. Oncolytics Biotech has established collaboration agreements with Merck KGaA and Pfizer Inc. to explore pelareorep in combination with other treatments for specific types of breast cancer. Additionally, the company is advancing its pipeline with projects such as Bracelet-1 for breast cancer and various cohorts for gastrointestinal cancer. Founded in 1998, Oncolytics Biotech aims to develop effective treatments for cancers that have not responded to existing therapies.

Satellos Bioscience is a private regenerative medicine company dedicated to developing innovative therapeutics aimed at stimulating or restoring muscle regeneration. The company is particularly focused on addressing severe disorders, with a key program centered on creating an oral therapeutic drug for Duchenne muscular dystrophy. This drug is designed to correct the dysregulation identified by Satellos as a fundamental cause of the disease's progressive nature. Through its research and development efforts, Satellos aims to provide effective treatments that enhance muscle regeneration and improve the quality of life for individuals affected by this debilitating condition.